Buys | $7,657 | 1 | 5 |
Sells | $122,300 | 21 | 95 |
Quimi Daphne | director | 1 | $7,657 | 0 | $0 | $7,657 |
Carr Douglas | SVP Finance & Operations | 0 | $0 | 5 | $2,710 | $-2,710 |
Farid Adrienne | Chief Operations Officer | 0 | $0 | 5 | $8,337 | $-8,337 |
Pfeiffenberger Brent | President and CEO | 0 | $0 | 2 | $28,554 | $-28,554 |
Russotti Gregory | See Remarks | 0 | $0 | 9 | $82,699 | $-82,699 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, …
Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $7,657 and sold $122,300 worth of Century Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $16M and sold $2.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Quimi Daphne (director) — $7,657.
The last purchase of 5,000 shares for transaction amount of $7,657 was made by Quimi Daphne (director) on 2024‑09‑12.
2025-03-10 | Sale | Pfeiffenberger Brent | President and CEO | 2,235 0.0027% | $0.61 | $1,375 | -2.17% | |
2025-03-10 | Sale | Carr Douglas | SVP Finance & Operations | 1,240 0.0015% | $0.61 | $763 | -2.17% | |
2025-03-10 | Sale | Russotti Gregory | See Remarks | 2,360 0.0028% | $0.61 | $1,451 | -2.17% | |
2025-03-10 | Sale | Farid Adrienne | Chief Operations Officer | 2,359 0.0028% | $0.61 | $1,451 | -2.17% | |
2025-02-18 | Sale | Pfeiffenberger Brent | President and CEO | 34,712 0.0413% | $0.78 | $27,180 | -19.75% | |
2025-02-03 | Sale | Carr Douglas | SVP Finance & Operations | 351 0.0004% | $0.78 | $274 | -9.35% | |
2025-02-03 | Sale | Farid Adrienne | Chief Operations Officer | 1,054 0.0012% | $0.78 | $822 | -9.35% | |
2024-11-04 | Sale | Carr Douglas | SVP Finance & Operations | 283 0.0003% | $1.23 | $347 | -21.03% | |
2024-11-04 | Sale | Farid Adrienne | Chief Operations Officer | 1,033 0.0012% | $1.23 | $1,267 | -21.03% | |
2024-09-12 | Quimi Daphne | director | 5,000 0.0059% | $1.53 | $7,657 | -20.78% | ||
2024-08-05 | Sale | Carr Douglas | SVP Finance & Operations | 289 0.0003% | $1.83 | $528 | -27.96% | |
2024-08-05 | Sale | Farid Adrienne | Chief Operations Officer | 1,073 0.0012% | $1.83 | $1,960 | -27.96% | |
2024-07-26 | Sale | Russotti Gregory | See Remarks | 586 0.0007% | $2.50 | $1,465 | -45.00% | |
2024-07-24 | Sale | Russotti Gregory | See Remarks | 1,600 0.002% | $2.52 | $4,029 | -41.60% | |
2024-07-23 | Sale | Russotti Gregory | See Remarks | 200 0.0002% | $2.50 | $500 | -43.95% | |
2024-06-20 | Sale | Russotti Gregory | See Remarks | 5,000 0.0052% | $2.84 | $14,179 | -45.72% | |
2024-06-05 | Sale | Russotti Gregory | See Remarks | 5,000 0.006% | $3.00 | $14,989 | -50.67% | |
2024-05-20 | Sale | Russotti Gregory | See Remarks | 5,000 0.006% | $3.00 | $14,978 | -49.17% | |
2024-05-06 | Sale | Russotti Gregory | See Remarks | 5,000 0.0076% | $3.12 | $15,619 | -51.42% | |
2024-05-03 | Sale | Carr Douglas | SVP Finance & Operations | 257 0.0004% | $3.11 | $798 | -49.17% |
Quimi Daphne | director | 5000 0.0059% | $2,981.50 | 1 | 0 | |
BAYER AKTIENGESELLSCHAFT | 10 percent owner | 12675838 14.9077% | $7.56M | 1 | 0 | <0.0001% |
Casdin Eli | director | 3206380 3.7709% | $1.91M | 1 | 0 | <0.0001% |
Versant Venture Capital VI, L.P. | 10 percent owner | 714095 0.8398% | $425,814.85 | 1 | 0 | <0.0001% |
$15,956,086 | 53 | 5.33% | $46.1M | |
$81,638,324 | 48 | 7.58% | $49.31M | |
$18,274,594 | 22 | -26.07% | $49.68M | |
$1,087,418 | 21 | 1.95% | $45.39M | |
$160,539,875 | 21 | -6.57% | $46.76M |
Increased Positions | 44 | +75.86% | 6M | +15.83% |
Decreased Positions | 20 | -34.48% | 7M | -16.72% |
New Positions | 15 | New | 1M | New |
Sold Out Positions | 10 | Sold Out | 2M | Sold Out |
Total Postitions | 82 | +41.38% | 40M | -0.89% |
Bain Capital Life Sciences Investors, Llc | $3,225.00 | 6.37% | 5.41M | 0 | 0% | 2024-12-31 |
Casdin Capital, Llc | $3,094.00 | 6.11% | 5.19M | +2M | +61.58% | 2024-12-31 |
Vr Adviser, Llc | $2,358.00 | 4.66% | 3.96M | -1M | -26.57% | 2024-12-31 |
Boxer Capital, Llc | $2,324.00 | 4.59% | 3.9M | -1M | -20.43% | 2024-09-30 |
Blackrock, Inc. | $1,810.00 | 3.57% | 3.04M | +47,328 | +1.58% | 2024-12-31 |
Fmr Llc | $1,510.00 | 2.98% | 2.53M | +12,363 | +0.49% | 2024-12-31 |
Vanguard Group Inc | $1,419.00 | 2.8% | 2.38M | -93,508 | -3.78% | 2024-12-31 |
Dafna Capital Management Llc | $1,016.00 | 2.01% | 1.7M | 0 | 0% | 2024-12-31 |
Millennium Management Llc | $958.00 | 1.89% | 1.61M | +1M | +1,041.79% | 2024-12-31 |
Syncona Portfolio Ltd | $723.00 | 1.43% | 1.21M | 0 | 0% | 2024-12-31 |